Long noncoding RNA Chast promotes cardiac remodeling
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibition of the long noncoding RNA Chast prevents pressure overload–induced cardiac remodeling in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [163]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797 · cited 1×
“To generate cardiac pressure overload, male C57BL/6N mice (8 to 10 weeks old) were subjected to TAC as described previously (29).”
MethodRetractedAn integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs
Rinn, J. L., Kertesz, M., Wang, J. K., Squazzo, S. L., Xu, X., Brugmann, S. A., Goodnough, L. H., Helms, J. A., Farnham, P. J., Segal, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.022 · Cited by 4,244 · cited 1×
“LncRNAs regulate pathways by diverse mechanisms including chromatin modification (3), transcriptional (4) and posttranscriptional regulation (5), and influencing subcellular trafficking (6, 7).”
BackgroundGenome Regulation by Long Noncoding RNAs
Rinn, J. L., & Chang, H. Y. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051410-092902 · Cited by 4,005 · cited 1×
“LncRNAs can function as guide strands influencing genes or proteins in trans (on distantly located genes) or in cis (on neighboring genes) (23).”
BackgroundOpen source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Java Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991
Kong, L., Zhang, Y., Ye, Z.-Q., Liu, X.-Q., Zhao, S.-Q., Wei, L., & Gao, G. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm391 · Cited by 2,803
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566 · cited 2×
“To determine whether Chast is regulated by NFAT activation, we tested Chast expression in hearts of calcineurin (Myh6-CnA) transgenic (TG) mice (15), where NFAT is constitutively active.”
BackgroundMethodLian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., Hsiao, C., Kamp, T. J., & Palecek, S. P. (2013) · Nature Protocols · doi:10.1038/nprot.2012.150 · Cited by 1,748
Cited by
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
“Silencing of Chast in vivo after TAC was beneficial in the mouse model, and the conservation of the lncRNA indicates the potential as a therapeutic target (277).”
BackgroundSelf-citationSmall and long non-coding RNAs: Past, present, and future
Chen, L.-L., & Kim, V. N. (2024) · Cell · doi:10.1016/j.cell.2024.10.024 · Cited by 425
Long non-coding RNA: Classification, biogenesis and functions in blood cells
Dahariya, S., Paddibhatla, I., Kumar, S., Raghuwanshi, S., Pallepati, A., & Gutti, R. K. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.04.011 · Cited by 413
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
“Kumarswamy et al.193 performed transcriptomics analyses of plasma lncRNAs in patients with cardiac remodelling post-AMI and identified LIPCAR (long intergenic non-coding RNA predicting cardiac remodelling) as potential biomarker for HF. Higher levels of LIPCAR were also associated with a higher risk of cardiovascular…”
BackgroundInfluentialSelf-citationThe long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy
Wang, Z., Zhang, X.-J., Ji, Y.-X., Zhang, P., Deng, K.-Q., Gong, J., Ren, S., Wang, X., Chen, I., Wang, H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4179 · Cited by 386
The long noncoding RNA Wisper controls cardiac fibrosis and remodeling
Micheletti, R., Plaisance, I., Abraham, B. J., Sarre, A., Ting, C.-C., Alexanian, M., Maric, D., Maison, D., Nemir, M., Young, R. A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai9118 · Cited by 349
Piccoli, M.-T., Gupta, S. K., Viereck, J., Foinquinos, A., Samolovac, S., Kramer, F. L., Garg, A., Remke, J., Zimmer, K., Batkai, S., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310624 · Cited by 344
“Besides, some roles of long noncoding RNAs (lncRNAs) in cardiomyocyte hypertrophy have been recently uncovered.(2) Nevertheless, the existence of functional lncRNAs in CFs remains largely unexplored, and it is unknown whether they undergo dysregulation in vivo during cardiac remodeling, playing a role in the developme…”
BackgroundSelf-citationRNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 331
Self-citationLiu, C.-Y., Zhang, Y.-H., Li, R.-B., Zhou, L.-Y., An, T., Zhang, R.-C., Zhai, M., Huang, Y., Yan, K.-W., Dong, Y.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02280-y · Cited by 330
Long noncoding RNAs in kidney and cardiovascular diseases
Lorenzen, J. M., & Thum, T. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.51 · Cited by 322
Self-citationLong Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy
Bär, C., Chatterjee, S., & Thum, T. (2016) · Circulation · doi:10.1161/circulationaha.116.023686 · Cited by 267
Self-citationYu, C., Li, L., Xie, F., Guo, S., Liu, F., Dong, N., & Wang, Y. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvx180 · Cited by 253
Lekka, E., & Hall, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13182 · Cited by 251
Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 210
Self-citationHeart Failure in Pediatric Patients With Congenital Heart Disease
Hinton, R. B., & Ware, S. M. (2017) · Circulation Research · doi:10.1161/circresaha.116.308996 · Cited by 205
Regulatory RNAs in Heart Failure
Gomes, C. P. D. C., Schroen, B., Kuster, G. M., Robinson, E. L., Ford, K., Squire, I. B., Heymans, S., Martelli, F., Emanueli, C., Devaux, Y., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.042474 · Cited by 188
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Self-citationLoganathan, T., & Doss C, G. P. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-022-00947-4 · Cited by 181
Diabetes Mellitus and Cardiovascular Disease: Emerging Therapeutic Approaches
Schmidt, A. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.310961 · Cited by 183
“cardiac remodeling in mice undergoing transverse aortic constriction.(64) In nondiabetic mice, Malat1 (metastasis-associated”
Miao, Y., Ajami, N. E., Huang, T.-S., Lin, F.-M., Lou, C.-H., Wang, Y.-T., Li, S., Kang, J., Munkacsi, H., Maurya, M. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02113-y · Cited by 177
Circular RNAs in Heart Failure
Devaux, Y., Creemers, E. E., Boon, R. A., Werfel, S., Thum, T., Engelhardt, S., Dimmeler, S., & Squire, I. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.801 · Cited by 178
Self-citationA macrophage-specific lncRNA regulates apoptosis and atherosclerosis by tethering HuR in the nucleus
Simion, V., Zhou, H., Haemmig, S., Pierce, J. B., Mendes, S., Tesmenitsky, Y., Pérez-Cremades, D., Lee, J. F., Chen, A. F., Ronda, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19664-2 · Cited by 172
Omura, J., Habbout, K., Shimauchi, T., Wu, W.-H., Breuils-Bonnet, S., Tremblay, E., Martineau, S., Nadeau, V., Gagnon, K., Mazoyer, F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047626 · Cited by 164
RNA Therapeutics in Cardiovascular Disease
Lucas, T., Bonauer, A., & Dimmeler, S. (2018) · Circulation Research · doi:10.1161/circresaha.117.311311 · Cited by 156
Gene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, A. N., Ali, H., Sinagra, G., & Giacca, M. (2020) · Circulation Research · doi:10.1161/circresaha.120.315855 · Cited by 163
Epigenetics in Cardiac Hypertrophy and Heart Failure
Liu, C., & Tang, W. H. W. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.011 · Cited by 166
“Although no clinical trials targeting lncRNAs were performed, several in vivo studies have shown that injection of lncRNA GapmeR such as GapmeR-Chast preserved or improved cardiac function in mice after pressure overload-induced cardiac hypertrophy and HF (74,78).”
BackgroundMethodGoh, K. Y., He, L., Song, J., Jinno, M., Rogers, A. J., Sethu, P., Halade, G. V., Rajasekaran, N. S., Liu, X., Prabhu, S. D., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101100 · Cited by 149
Long non-coding RNAs involved in autophagy regulation
Yang, L., Wang, H., Shen, Q., Feng, L., & Jin, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.464 · Cited by 148
“and possibly ATG5 expression to induce cardiomyocyte hypertrophy (Figure 5).(120) This study sheds light on the”
BackgroundLncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d
Liang, H., Pan, Z., Zhao, X., Liu, L., Sun, J., Su, X., Xu, C., Zhou, Y., Zhao, D., Xu, B., et al. (2018) · Theranostics · doi:10.7150/thno.20846 · Cited by 144
“Recently, long non-coding RNAs (lncRNAs) have been recognized as novel factors that regulate the initiation and progression of cardiac diseases by modulating chromatin remodeling, via transcriptional and posttranscriptional control and by competitively binding miRNAs[5, 14, 15].”
BackgroundInfluentialZhao, X., Su, L., He, X., Zhao, B., & Miao, J. (2019) · Autophagy · doi:10.1080/15548627.2019.1598750 · Cited by 140
Emerging connections between RNA and autophagy
Frankel, L. B., Lubas, M., & Lund, A. H. (2017) · Autophagy · doi:10.1080/15548627.2016.1222992 · Cited by 135
Long Non-coding RNAs: At the Heart of Cardiac Dysfunction?
Hobuß, L., Bär, C., & Thum, T. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00030 · Cited by 132
Self-citationTargeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy
Viereck, J., Bührke, A., Foinquinos, A., Chatterjee, S., Kleeberger, J., Xiao, K., Janssen‐Peters, H., Bátkai, S., Ramanujam, D. P., Kraft, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa519 · Cited by 138
Self-citationThe lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214
Lv, L., Li, T., Li, X., Xu, C., Liu, Q., Jiang, H., Li, Y., Liu, Y., Yan, H., Huang, Q., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.018 · Cited by 119
“Chast (Cardiac Hypertrophy-Associated Transcript) is another pro-hypertrophy lncRNA, which is upregulated in hypertrophic hearts by negatively regulating Plekhm1 to restrain CM autophagy and induce hypertrophy.(39) CHRF (Cardiac Hypertrophy-Related Factor) is upregulated in both the hypertrophic mouse heart and human…”
BackgroundlncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth
Li, H., Trager, L. E., Liu, X., Hastings, M. H., Xiao, C., Guerra, J. R. B., To, S., Li, G., Yeri, A., Rodosthenous, R. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056850 · Cited by 118
Liang, H., Su, X., Wu, Q., Shan, H., Lv, L., Yu, T., Zhao, X., Sun, J., Yang, R., Zhang, L., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1659610 · Cited by 123
Translational Perspective on Epigenetics in Cardiovascular Disease
van der Harst, P., Windt, L. J. D., & Chambers, J. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.067 · Cited by 142
“(gapmer) prevented and regressed pressure overload– induced adverse cardiac remodeling in the mouse without signs of side effects (124).”
BackgroundStępień, E. Ł., Costa, M. C., Kurc, S., Drożdż, A., Cortez‐Dias, N., & Enguita, F. J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.35 · Cited by 109
Gomes, C. P. C., Spencer, H., Ford, K. L., Michel, L. Y. M., Baker, A. H., Emanueli, C., Balligand, J.-L., & Devaux, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.07.014 · Cited by 109
“One example is CHAST, for which the GapmeR-mediated silencing attenuated transverse aortic constriction-induced cardiac remodeling in mice.(15) No apparent side effects were observed due to treatment with GapmeRs.”
BackgroundInfluentialThe emergence of noncoding RNAs as Heracles in autophagy
Zhang, J., Wang, P., Wan, L., Xu, S., & Pang, D. (2017) · Autophagy · doi:10.1080/15548627.2017.1312041 · Cited by 105
“Suppression of Chast attenuates or reverses cardiomyocyte hypertrophy.(101)”
BackgroundTrembinski, D. J., Bink, D. I., Theodorou, K., Sommer, J., Fischer, A., van Bergen, A. S., Kuo, C., Costa, I. G., Schürmann, C., Leisegang, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15995-2 · Cited by 103
Self-citationDas, S., Shah, R. V., Dimmeler, S., Freedman, J. E., Holley, C. L., Lee, J., Moore, K. J., Musunuru, K., Wang, D., Xiao, J., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000062 · Cited by 124
Long noncoding RNA FTX regulates cardiomyocyte apoptosis by targeting miR-29b-1-5p and Bcl2l2
Long, B., Li, N., Xu, X., Li, X., Xu, X., Guo, D., Zhang, D., Wu, Z., & Zhang, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.030 · Cited by 112
Huang, Z., Tian, L.-H., Yang, B., & Guo, R. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3799 · Cited by 99
“Besides, lncRNA cardiac hypertrophy-associated transcript is detected using global lncRNA expression profiling, modulating cardiomyocyte hypertrophy (Viereck et al., 2016).”
Long Noncoding RNAs in Pathological Cardiac Remodeling: A Review of the Update Literature
Zhou, H., Wang, B., Yang, Y.-X., Jia, Q.-J., Zhang, A., Qi, Z., & Zhang, J. (2019) · BioMed Research International · doi:10.1155/2019/7159592 · Cited by 105
“Themechanism by which it drives hypertrophy is involved in the negative regulation of pleckstrin homology domain-containing protein family M member 1(Plekhm1), the gene located on its opposite strand, thus hindering cardiomyocyte autophagy and facilitating hypertrophy [64].”
Long noncoding RNA Meg3 regulates cardiomyocyte apoptosis in myocardial infarction
Wu, H., Zhao, Z., Liu, J., Hao, K., You, Y., Han, X., Li, J., Wang, Y., Lei, W., Dong, N., et al. (2018) · Gene Therapy · doi:10.1038/s41434-018-0045-4 · Cited by 100
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 100
Signaling by LncRNAs: Structure, Cellular Homeostasis, and Disease Pathology
Nadhan, R., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2022) · Cells · doi:10.3390/cells11162517 · Cited by 107
“Cardiovascular Diseases APF [80] BANCR [81] CHAER [82] CHAST [83] CHRF [84] CHROME [85] Giver [86] HOTTIP [87] LINC00968 [88] lnc-Ang362 [89] lnc-AK098656 [90] MIAT [91] MIRT1 [92] KCNQ1OT1 [93] UCA1 [94] FTX [95] GAS5 [96] HOTAIR [97] lincRNA-p21 [98,99] MHRT [100] NEXN-AS1 [101] SENCR [102]”
BackgroundLong Non-Coding RNAs in Cardiac Remodeling
Shen, S., Jiang, H., Bei, Y., Xiao, J., & Li, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471913 · Cited by 94
Hao, K., Lei, W., Wu, H., Wu, J., Yang, Z., Yan, S., Lu, X., Li, J., Xia, X., Han, X., et al. (2019) · Theranostics · doi:10.7150/thno.33920 · Cited by 95
“Although previous studies have revealed beneficial effects of several lncRNAs on pathological fibrosis, most of them were cardiomyocyteenrichment [19-21].”
Lin, H., Zhu, Y., Zheng, C., Hu, D., Ma, S., Chen, L., Wang, Q., Chen, Z., Xie, J., Yan, Y., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.047000 · Cited by 90
Wan, J.-J., Zhang, Z., Wu, C., Tian, S.-S., Zang, Y., Jin, G., Sun, Q.-Y., Wang, P., Luan, X., Yang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01660-9 · Cited by 89
Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury
Kölling, M., Genschel, C., Kaucsár, T., Hübner, A., Rong, S., Schmitt, R., Sörensen-Zender, I., Haddad, G., Kistler, A. D., Seeger, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21720-3 · Cited by 87
Self-citationLong noncoding RNAs in cardiovascular disease, diagnosis, and therapy
Haemmig, S., Simion, V., Yang, D., Deng, Y., & Feinberg, M. W. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000454 · Cited by 102
Non-coding RNAs: emerging players in cardiomyocyte proliferation and cardiac regeneration
Abbas, N., Perbellini, F., & Thum, T. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-0816-0 · Cited by 85
Self-citationLong Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity
Cipolla, G. A., de Oliveira, J. C., Salviano‐Silva, A., Lobo‐Alves, S. C., Lemos, D. S., Oliveira, L., Jucoski, T. S., Mathias, C., Pedroso, G. A., Zambalde, É. P., et al. (2018) · Non-Coding RNA · doi:10.3390/ncrna4020013 · Cited by 84
“Inhibition of CHAST shows some therapeutic relevance to prevent or attenuate cardiac remodeling before and after induction of hypertrophy, respectively [71].”
BackgroundThe Implications of ncRNAs in the Development of Human Diseases
López‐Jiménez, E., & Andrés‐León, E. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010017 · Cited by 90
González, A., Richards, M., de Boer, R. A., Thum, T., Arfsten, H., Hülsmann, M., Falcão‐Pires, I., Díez, J., Foo, R., Chan, M. Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2493 · Cited by 86
Self-citationMuscle Atrophy: Present and Future
Cao, R. Y., Li, J., Dai, Q., Li, Q. X., & Yang, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_29 · Cited by 83
Bei, Y., Zhu, Y., Zhou, J., Ai, S., Yao, J., Yin, M., Hu, M., Qi, W., Spanos, M., Li, L., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067592 · Cited by 85
Bischoff, F. C., Werner, A., John, D., Boeckel, J., Melissari, M., Grote, P., Glaser, S.-F., Demolli, S., Uchida, S., Michalik, K., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.310531 · Cited by 72
Epigenomes in Cardiovascular Disease
Rosa‐Garrido, M., Chapski, D. J., & Vondriska, T. M. (2018) · Circulation Research · doi:10.1161/circresaha.118.311597 · Cited by 77
“145 Interestingly, lncRNAs like Malat1 in vascular tissues 146 and Chast in cardiac tissues 147 are nuclear localized and regulate expression of nearby genes although it remains to be tested whether they accomplish these actions through recruitment of chromatin complexes.”
Noncoding RNAs in age-related cardiovascular diseases
Jusic, A., Thomas, P. B., Wettinger, S. B., Dogan, S., Farrugia, R., Gaetano, C., Tuna, B. G., Pinet, F., Robinson, E. L., Tual-Chalot, S., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101610 · Cited by 70
Non-Coding RNAs: Prevention, Diagnosis, and Treatment in Myocardial Ischemia–Reperfusion Injury
Marinescu, M.-C., Lazăr, A.-L., Marta, M. M., Cozma, A., & Cătană, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052728 · Cited by 75
Long Noncoding RNAs and Cardiac Disease
Greco, S., Salgado‐Somoza, A., Devaux, Y., & Martelli, F. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7126 · Cited by 72
Recent advances on the roles of LncRNAs in cardiovascular disease
Fang, Y., Xu, Y., Wang, R., Hu, L., Guo, D. S., Xue, F., Guo, W., Zhang, D., Hu, J., Li, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15880 · Cited by 67
Long non-coding RNAs act as regulators of cell autophagy in diseases
Xu, Z., Yan, Y., Qian, L., & Gong, Z. (2017) · Oncology Reports · doi:10.3892/or.2017.5416 · Cited by 69
Han, X., Zhang, J., Liu, Y., Fan, X., Ai, S., Luo, Y., Li, X., Jin, H., Luo, S., Zheng, H., et al. (2019) · Development · doi:10.1242/dev.176198 · Cited by 74
Correia, C. C. M., Rodrigues, L. F., Pelozin, B. R. D. A., de Oliveira, E. M., & Fernandes, T. M. (2021) · Non-Coding RNA · doi:10.3390/ncrna7040065 · Cited by 71
Li, H., Zhao, X., Shan, H., & Liang, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.010 · Cited by 72
Noncoding RNAs in Cardiac Hypertrophy
Li, Y., Liang, Y., Zhu, Y., Zhang, Y., & Bei, Y. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9797-x · Cited by 66
Long non-coding RNAs in the failing heart and vasculature
Hermans-Beijnsberger, S., van Bilsen, M., & Schroen, B. L. M. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.04.002 · Cited by 67
Pathobiology of pulmonary artery hypertension: role of long non-coding RNAs
Zahid, K. R., Raza, U., Chen, J., Raj, U. J., & Gou, D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa050 · Cited by 66
Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure
Liu, Y., Deng, J., Ma, W., Qiao, A., Xu, S., Yu, Y., Boriboun, C., Xiang, K., Han, D., Erñst, P., et al. (2021) · Theranostics · doi:10.7150/thno.50990 · Cited by 64
“At present, only a small proportion of lncRNAs have been functionally validated in cardiovascular biology, including heart development [12, 13] and hypertrophy [14-16].”
BackgroundThe Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling
Gao, J., Xu, W., Wang, J., Wang, K., & Li, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030608 · Cited by 64
LncRNA PCFL promotes cardiac fibrosis via miR-378/GRB2 pathway following myocardial infarction
Sun, F., Zhuang, Y., Zhu, H., Wu, H., Li, D., Zhan, L., Yang, W., Yuan, Y., Xie, Y., Yang, S., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.011 · Cited by 62
MicroRNA and diabetic retinopathy—biomarkers and novel therapeutics
Smit‐McBride, Z., & Morse, L. S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5189 · Cited by 65
“In vivo, LNA anti-miR can inhibit target molecules up to 15 weeks in live animals (88-91).”
BackgroundGenerating 3D human cardiac constructs from pluripotent stem cells
Liu, C., Feng, X., Li, G., Gokulnath, P., & Xiao, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103813 · Cited by 62
Chen, L., Yan, K., Liu, X., Wang, W., Li, C., Li, M., & Qiu, C. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0980-4 · Cited by 62
Liu, N., Kataoka, M., Wang, Y., Pu, L., Dong, X., Fu, X., Zhang, F., Gao, F., Liang, T., Pei, J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00887-3 · Cited by 61
Deciphering Non-coding RNAs in Cardiovascular Health and Disease
Das, A., Samidurai, A., & Salloum, F. N. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00073 · Cited by 60
“Cardiac Hypertrophy-Associated Transcript (Chast) is another novel cardiomyocyte-specific lncRNA known to be upregulated in TAC-induced hypertrophy in mice and aortic stenosis patients (305).”
BackgroundHamdani, N., Costantino, S., Mügge, A., Lebeche, D., Tschöpe, C., Thum, T., & Paneni, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab197 · Cited by 59
“The lncRNA Chast is also implicated in autophagy inhibition and hypertrophic remodelling by regulating Pleckstrin homology domain-containing protein family M member 1 (PLEKHM1).(111) Along the same line, the lncRNA CHAER interacts with the methyltransferase PRC2, thus reducing the repressive H3K27me3 marks at the Leve…”
BackgroundSelf-citationmiR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity
Gupta, S. K., Garg, A., Avramopoulos, P., Engelhardt, S. H., Streckfuß‐Bömeke, K., Bátkai, S., & Thum, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.004 · Cited by 56
“AAV9 and AAV6 were produced as previously described.(30) AAV9 was injected intravenously at a dose of 2 10(12) viral particles.”
MethodSelf-citationThe functions of LncRNA in the heart
Wang, Y., & Sun, X. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108249 · Cited by 61
Circ-SIRT1 inhibits cardiac hypertrophy via activating SIRT1 to promote autophagy
Wang, W., Wang, L., Yang, M., Wu, C., Lan, R., Wang, W., & Li, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04059-y · Cited by 63
“Interestingly, existing evidence has clarified the negative relation of autophagy to CH, that is, promoting autophagy may attenuate CH [16, 31].”
BackgroundTargeting Non-coding RNA in Vascular Biology and Disease
Hung, J., Miscianinov, V., Sluimer, J. C., Newby, D. E., & Baker, A. H. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01655 · Cited by 57
“Notably, the in vivo delivery of GapmeR targeting Chast resulted in decrease in pathological cardiac remodelling with no side effects (Viereck et al., 2016).”
BackgroundYu, J., Yang, Y., Xu, Z., Lan, C., Chen, C., Li, C., Chen, Z., Cheng, Y., Xia, X., Liao, Q., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006525 · Cited by 55
Wang, H., Maimaitiaili, R., Yao, J., Xie, Y., Qiang, S., Hu, F., Li, X., Shi, C., Jia, P., Yang, H., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17574 · Cited by 54
Yuan, Y., Wang, J., Chen, Q., Wu, Q., Deng, W., Zhou, H., & Shen, D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.02.014 · Cited by 54
Zhang, Y., Du, W., & Yang, B. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.011 · Cited by 52
Sweta, S., Dudnakova, T., Sudheer, S., Baker, A. H., & Bhushan, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00228 · Cited by 64
A novel pathway regulates social hierarchy via lncRNA AtLAS and postsynaptic synapsin IIb
Ma, M., Xiong, W., Hu, F., Deng, M., Huang, X., Chen, J., Man, H., Lu, Y., Liu, D., & Zhu, L. (2020) · Cell Research · doi:10.1038/s41422-020-0273-1 · Cited by 51
LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy
Fan, J., Li, H., Xie, R., Zhang, X., Nie, X., Shi, X., Zhan, J., Yin, Z., Zhao, Y., Dai, B., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318437 · Cited by 53
Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension
Leimena, C., & Qiu, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040927 · Cited by 57
“Nuclear lncRNAs, on the other hand, could be downregulated using the GapmeRs system, by heteroduplex formation with the target lncRNAs for cleavage by RNase H [108,109].”
BackgroundThe role and molecular mechanism of epigenetics in cardiac hypertrophy
Lei, H. C., Hu, J., Sun, K., & Xu, D. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09959-3 · Cited by 53
Autophagy in cardiovascular diseases: role of noncoding RNAs
Gao, J., Chen, X., Shan, C., Wang, Y., Li, P., & Shao, K. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.039 · Cited by 57
“Therefore, the increased MALAT1 expression induced by H/R injury inhibits cardiomyocyte proliferation and enhances apoptosis through autophagy inhibition by regulating TSC2-mTOR signaling activity.97 lncRNAs, autophagy, and cardiac hypertrophy lncRNA-transcription regulation Viereck et al.101 observed a significant up…”
BackgroundInteractions between microRNAs and long non-coding RNAs in cardiac development and repair
Rotini, A., Martínez‐Sarrà, E., Pozzo, E., & Sampaolesi, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.029 · Cited by 51
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 55
Long noncoding RNA in cardiac aging and disease
Lozano‐Vidal, N., Bink, D. I., & Boon, R. A. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz046 · Cited by 53
“It is unknown what the specific mechanism is that allows Chast to interfere with Plekhm1 expression (Viereck et al., 2016).”
BackgroundLong noncoding RNA Cfast regulates cardiac fibrosis
Zhang, F., Fu, X., Kataoka, M., Liu, N., Wang, Y., Gao, F., Liang, T., Dong, X., Pei, J., Hu, X., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.11.013 · Cited by 53
Metadata
- Authors
- Viereck, J., Kumarswamy, R., Foinquinos, A., Xiao, K., Avramopoulos, P., Kunz, M., Dittrich, M., Maetzig, T., Zimmer, K., Remke, J., Just, A., Fendrich, J., Scherf, K., Bolesani, E., Schambach, A., Weidemann, F., Zweigerdt, R., de Windt, L. J., Engelhardt, S., Dandekar, T., Batkai, S., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- German Centre for Cardiovascular Research (DE)
- University of Würzburg (DE)
- Department of Cardiology, Maastricht University, 6202 AZ Maastricht, Netherlands.
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Integriertes Forschungs- und Behandlungszentrum Transplantation (IFB-Tx), Hannover Medical School, D-30625 Hannover, Germany.
- Corresponding author
- Viereck, Janika
- Kumarswamy, Regalla
- Foinquinos, Ariana
- Thum, Thomas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-02-17
- Volume
- 8
- Issue
- 326
- Pages
- 326ra22-326ra22
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2283987082
- Cited by
- 370
- References
- 44
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 20 · 2023: 35 · 2022: 35 · 2021: 32 · 2020: 58 · 2019: 56 · 2018: 45 · 2017: 43 · 2016: 15
- FWCI
- 43.72
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Integrierte Forschungs- und Behandlungszentrum Transplantation (BMBF 01EO1302)
- Deutsche Forschungsgemeinschaft (TH 903/10-1, RE 3523/1-1)
- REBIRTH Excellence Cluster
- Fondation Leducq
- European Research Council
- Hannover Biomedical Research School
- Bayerische Forschungsstiftung
- German Research Foundation (EXC62/3, ZW 64/4-1)
- German Ministry for Education and Science (13N12606)
- Innovative Medicines Initiative (115439-2)
- European Union (FP7/2007-2013)
- European Federation of Pharmaceutical Industries and Associations
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- long non-coding RNA, cardiac remodeling, cardiomyocyte hypertrophy, pressure overload, transverse aortic constriction, aortic stenosis, autophagy, PLSCR1, lncRNA expression profiling, heart disease
- MeSH terms
- Animals, Base Sequence, Gene Expression Regulation, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Molecular Sequence Data, Pressure, Signal Transduction, Ventricular Remodeling, Myocytes, Cardiac, NFATC Transcription Factors, Translational Research, Biomedical, RNA, Long Noncoding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.